

# Michele Baccarani

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8138170/publications.pdf>

Version: 2024-02-01

309  
papers

28,841  
citations

20759

60  
h-index

5101

166  
g-index

311  
all docs

311  
docs citations

311  
times ranked

12819  
citing authors

#	ARTICLE	IF	CITATIONS
1	Imatinib Compared with Interferon and Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia. <i>New England Journal of Medicine</i> , 2003, 348, 994-1004.	13.9	3,227
2	Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid Leukemia. <i>New England Journal of Medicine</i> , 2006, 355, 2408-2417.	13.9	3,212
3	European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. <i>Blood</i> , 2013, 122, 872-884.	0.6	1,743
4	Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia. <i>New England Journal of Medicine</i> , 2010, 362, 2260-2270.	13.9	1,411
5	Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet. <i>Journal of Clinical Oncology</i> , 2009, 27, 6041-6051.	0.8	1,188
6	Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. <i>Blood</i> , 2006, 108, 1809-1820.	0.6	1,184
7	Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. <i>Blood</i> , 2006, 108, 28-37.	0.6	1,117
8	Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia. <i>New England Journal of Medicine</i> , 2017, 376, 917-927.	13.9	926
9	A New Prognostic Score for Survival of Patients With Chronic Myeloid Leukemia Treated With Interferon Alfa Writing Committee for the Collaborative CML Prognostic Factors Project Group. <i>Journal of the National Cancer Institute</i> , 1998, 90, 850-859.	3.0	728
10	Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial. <i>Journal of Clinical Oncology</i> , 2016, 34, 2333-2340.	0.8	724
11	Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. <i>Blood</i> , 2007, 109, 2303-2309.	0.6	563
12	Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). <i>Blood</i> , 2012, 119, 1123-1129.	0.6	520
13	BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet. <i>Blood</i> , 2011, 118, 1208-1215.	0.6	486
14	Contribution of ABL Kinase Domain Mutations to Imatinib Resistance in Different Subsets of Philadelphia-Positive Patients: By the GIMEMA Working Party on Chronic Myeloid Leukemia. <i>Clinical Cancer Research</i> , 2006, 12, 7374-7379.	3.2	475
15	Chronic myeloid leukaemia. <i>Lancet, The</i> , 2007, 370, 342-350.	6.3	423
16	Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score. <i>Blood</i> , 2011, 118, 686-692.	0.6	413
17	Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. <i>Blood</i> , 2007, 109, 3207-3213.	0.6	400
18	Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. <i>Blood</i> , 2011, 118, 6521-6528.	0.6	395

#	ARTICLE	IF	CITATIONS
19	Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial. <i>Blood</i> , 2018, 132, 393-404.	0.6	392
20	Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION). <i>Blood</i> , 2014, 123, 494-500.	0.6	364
21	Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase. <i>Blood</i> , 2007, 109, 4143-4150.	0.6	352
22	ABL Mutations in Late Chronic Phase Chronic Myeloid Leukemia Patients With Up-Front Cytogenetic Resistance to Imatinib Are Associated With a Greater Likelihood of Progression to Blast Crisis and Shorter Survival: A Study by the GIMEMA Working Party on Chronic Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2005, 23, 4100-4109.	0.8	350
23	Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results. <i>Blood</i> , 2011, 117, 1141-1145.	0.6	344
24	Imatinib plus steroids induces complete remissions and prolonged survival in elderly Philadelphia chromosome-positive patients with acute lymphoblastic leukemia without additional chemotherapy: results of the Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA) LAL0201-B protocol. <i>Blood</i> , 2007, 109, 3676-3678.	0.6	336
25	BCR-ABL1 Compound Mutations Combining Key Kinase Domain Positions Confer Clinical Resistance to Ponatinib in Ph Chromosome-Positive Leukemia. <i>Cancer Cell</i> , 2014, 26, 428-442.	7.7	292
26	Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia. <i>Blood</i> , 2008, 111, 1834-1839.	0.6	284
27	Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure. <i>Blood</i> , 2012, 119, 3403-3412.	0.6	281
28	Phase III, Randomized, Open-Label Study of Daily Imatinib Mesylate 400 mg Versus 800 mg in Patients With Newly Diagnosed, Previously Untreated Chronic Myeloid Leukemia in Chronic Phase Using Molecular End Points: Tyrosine Kinase Inhibitor Optimization and Selectivity Study. <i>Journal of Clinical Oncology</i> , 2010, 28, 424-430.	0.8	265
29	Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population. <i>Blood</i> , 2011, 118, 4554-4560.	0.6	221
30	Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2016, 17, 612-621.	5.1	214
31	The efficacy of imatinib mesylate in patients with FIP1L1-PDGFR $\alpha$ -positive hypereosinophilic syndrome. Results of a multicenter prospective study. <i>Haematologica</i> , 2007, 92, 1173-1179.	1.7	198
32	Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study. <i>Blood</i> , 2009, 113, 4497-4504.	0.6	173
33	Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain. <i>Haematologica</i> , 2007, 92, 401-404.	1.7	172
34	Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors. <i>Blood</i> , 2009, 114, 2168-2171.	0.6	160
35	A randomized study of interferon- $\alpha$ versus interferon- $\beta$ and low-dose arabinosyl cytosine in chronic myeloid leukemia. <i>Blood</i> , 2002, 99, 1527-1535.	0.6	158
36	Unraveling the complexity of tyrosine kinase inhibitor-resistant populations by ultra-deep sequencing of the BCR-ABL kinase domain. <i>Blood</i> , 2013, 122, 1634-1648.	0.6	152

#	ARTICLE	IF	CITATIONS
37	A review of the European LeukemiaNet recommendations for the management of CML. <i>Annals of Hematology</i> , 2015, 94, 141-147.	0.8	134
38	Tyrosine kinase inhibitors in chronic myeloid leukaemia: which, when, for whom?. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 141-154.	12.5	134
39	Impact of dose intensity of ponatinib on selected adverse events: Multivariate analyses from a pooled population of clinical trial patients. <i>Leukemia Research</i> , 2016, 48, 84-91.	0.4	130
40	The prognosis for patients with chronic myeloid leukemia who have clonal cytogenetic abnormalities in Philadelphia chromosome-negative cells. <i>Cancer</i> , 2007, 110, 1509-1519.	2.0	121
41	Denaturing-HPLC-Based Assay for Detection of ABL Mutations in Chronic Myeloid Leukemia Patients Resistant to Imatinib. <i>Clinical Chemistry</i> , 2004, 50, 1205-1213.	1.5	120
42	Additional chromosomal abnormalities in Philadelphia-positive clone: adverse prognostic influence on frontline imatinib therapy: a GIMEMA Working Party on CML analysis. <i>Blood</i> , 2012, 120, 761-767.	0.6	110
43	Hydroxyurea-related toxicity in 3,411 patients with Ph-negative MPN. <i>American Journal of Hematology</i> , 2012, 87, 552-554.	2.0	105
44	Plasma exposure of imatinib and its correlation with clinical response in the Tyrosine Kinase Inhibitor Optimization and Selectivity Trial. <i>Haematologica</i> , 2012, 97, 731-738.	1.7	103
45	Treatment with PF-04449913, an oral smoothened antagonist, in patients with myeloid malignancies: a phase 1 safety and pharmacokinetics study. <i>Lancet Haematology</i> , 2015, 2, e339-e346.	2.2	102
46	Phase 3 study of nilotinib vs imatinib in Chinese patients with newly diagnosed chronic myeloid leukemia in chronic phase: ENESTchina. <i>Blood</i> , 2015, 125, 2771-2778.	0.6	102
47	Variant Philadelphia translocations: molecular-cytogenetic characterization and prognostic influence on frontline imatinib therapy, a GIMEMA Working Party on CML analysis. <i>Blood</i> , 2011, 117, 6793-6800.	0.6	98
48	Frontline imatinib treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CML Working Party. <i>Blood</i> , 2011, 117, 5591-5599.	0.6	97
49	Imatinib and pegylated human recombinant interferon- $\beta$ in early chronic-phase chronic myeloid leukemia. <i>Blood</i> , 2004, 104, 4245-4251.	0.6	96
50	Association between imatinib transporters and metabolizing enzymes genotype and response in newly diagnosed chronic myeloid leukemia patients receiving imatinib therapy. <i>Haematologica</i> , 2013, 98, 193-200.	1.7	96
51	Monitoring treatment of chronic myeloid leukemia. <i>Haematologica</i> , 2008, 93, 161-169.	1.7	88
52	Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients. <i>Blood</i> , 2016, 127, 703-712.	0.6	87
53	The proportion of different BCR-ABL1 transcript types in chronic myeloid leukemia. An international overview. <i>Leukemia</i> , 2019, 33, 1173-1183.	3.3	83
54	Cost-effectiveness of Tyrosine Kinase Inhibitor Treatment Strategies for Chronic Myeloid Leukemia in Chronic Phase After Generic Entry of Imatinib in the United States. <i>Journal of the National Cancer Institute</i> , 2016, 108, djw003.	3.0	82

#	ARTICLE	IF	CITATIONS
55	The BCR-ABL1 transcript type influences response and outcome in Philadelphia chromosome-positive chronic myeloid leukemia patients treated frontline with imatinib. <i>American Journal of Hematology</i> , 2017, 92, 797-805.	2.0	71
56	Molecular response to imatinib in late chronic-phase chronic myeloid leukemia. <i>Blood</i> , 2004, 103, 2284-2290.	0.6	69
57	Definitions, methodological and statistical issues for phase 3 clinical trials in chronic myeloid leukemia: a proposal by the European LeukemiaNet. <i>Blood</i> , 2012, 119, 5963-5971.	0.6	69
58	Next-generation deep sequencing improves detection of BCR-ABL1 kinase domain mutations emerging under tyrosine kinase inhibitor treatment of chronic myeloid leukemia patients in chronic phase. <i>Journal of Cancer Research and Clinical Oncology</i> , 2015, 141, 887-899.	1.2	67
59	Managing chronic myeloid leukemia for treatment-free remission: a proposal from the GIMEMA CML WP. <i>Blood Advances</i> , 2019, 3, 4280-4290.	2.5	66
60	First Report of the Gimema LAL1811 Phase II Prospective Study of the Combination of Steroids with Ponatinib As Frontline Therapy of Elderly or Unfit Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. <i>Blood</i> , 2017, 130, 99-99.	0.6	63
61	Chronic myeloid leukemia: a prospective comparison of interphase fluorescence in situ hybridization and chromosome banding analysis for the definition of complete cytogenetic response: a study of the GIMEMA CML WP. <i>Blood</i> , 2009, 114, 4939-4943.	0.6	62
62	Prospective assessment of NGS-detectable mutations in CML patients with nonoptimal response: the NEXT-in-CML study. <i>Blood</i> , 2020, 135, 534-541.	0.6	61
63	Response definitions and European LeukemiaNet Management recommendations. <i>Best Practice and Research in Clinical Haematology</i> , 2009, 22, 331-341.	0.7	60
64	Results of high-dose imatinib mesylate in intermediate Sokal risk chronic myeloid leukemia patients in early chronic phase: a phase 2 trial of the GIMEMA CML Working Party. <i>Blood</i> , 2009, 113, 3428-3434.	0.6	59
65	Observational study of chronic myeloid leukemia Italian patients who discontinued tyrosine kinase inhibitors in clinical practice. <i>Haematologica</i> , 2019, 104, 1589-1596.	1.7	58
66	Deletions of the Derivative Chromosome 9 Do Not Influence the Response and the Outcome of Chronic Myeloid Leukemia in Early Chronic Phase Treated With Imatinib Mesylate: GIMEMA CML Working Party Analysis. <i>Journal of Clinical Oncology</i> , 2010, 28, 2748-2754.	0.8	56
67	Management of pregnant chronic myeloid leukemia patients. <i>Expert Review of Hematology</i> , 2016, 9, 781-791.	1.0	55
68	The EUTOS long-term survival (ELTS) score is superior to the Sokal score for predicting survival in chronic myeloid leukemia. <i>Leukemia</i> , 2020, 34, 2138-2149.	3.3	55
69	Front-line treatment of Philadelphia positive chronic myeloid leukemia with imatinib and interferon- $\alpha$ : 5-year outcome. <i>Haematologica</i> , 2008, 93, 770-774.	1.7	53
70	Safety and Efficacy of Dasatinib Versus Imatinib by Baseline Cardiovascular Comorbidity In Patients with Chronic Myeloid Leukemia In Chronic Phase (CML-CP): Analysis of the DASISION Trial. <i>Blood</i> , 2010, 116, 2286-2286.	0.6	53
71	Next-generation sequencing for sensitive detection of BCR-ABL1 mutations relevant to tyrosine kinase inhibitor choice in imatinib-resistant patients. <i>Oncotarget</i> , 2016, 7, 21982-21990.	0.8	52
72	High-risk additional chromosomal abnormalities at low blast counts herald death by CML. <i>Leukemia</i> , 2020, 34, 2074-2086.	3.3	50

#	ARTICLE	IF	CITATIONS
73	Effects and outcome of a policy of intermittent imatinib treatment in elderly patients with chronic myeloid leukemia. <i>Blood</i> , 2013, 121, 5138-5144.	0.6	49
74	Long-term response to imatinib is not affected by the initial dose in patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: final update from the Tyrosine Kinase Inhibitor Optimization and Selectivity (TOPS) study. <i>International Journal of Hematology</i> , 2014, 99, 616-624.	0.7	47
75	Targeted therapy and the T315I mutation in Philadelphia-positive leukemias. <i>Haematologica</i> , 2007, 92, 437-439.	1.7	46
76	Bortezomib (Velcade®)-Thalidomide-Dexamethasone (VTD) vs Thalidomide-Dexamethasone (TD) in Preparation for Autologous Stem-Cell (SC) Transplantation (ASCT) in Newly Diagnosed Multiple Myeloma (MM).. <i>Blood</i> , 2007, 110, 73-73.	0.6	45
77	Imatinib mesylate for the treatment of chronic myeloid leukemia. <i>Expert Review of Anticancer Therapy</i> , 2008, 8, 853-864.	1.1	40
78	Choosing the Best Second-Line Tyrosine Kinase Inhibitor in Imatinib-Resistant Chronic Myeloid Leukemia Patients Harboring Bcr-Abl Kinase Domain Mutations: How Reliable Is the IC50?. <i>Oncologist</i> , 2011, 16, 868-876.	1.9	40
79	Long-term outcome of a phase 2 trial with nilotinib 400 mg twice daily in first-line treatment of chronic myeloid leukemia. <i>Haematologica</i> , 2015, 100, 1146-1150.	1.7	39
80	Tyrosine kinase inhibitors in Ph+ acute lymphoblastic leukaemia: facts and perspectives. <i>Annals of Hematology</i> , 2016, 95, 681-693.	0.8	39
81	Pancreatic enzyme elevation in chronic myeloid leukemia patients treated with nilotinib after imatinib failure. <i>Haematologica</i> , 2009, 94, 1758-1761.	1.7	35
82	Chronic myeloid leukemia: the concepts of resistance and persistence and the relationship with the BCR-ABL1 transcript type. <i>Leukemia</i> , 2019, 33, 2358-2364.	3.3	35
83	No influence of BCR-ABL1 transcript types e13a2 and e14a2 on long-term survival: results in 1494 patients with chronic myeloid leukemia treated with imatinib. <i>Journal of Cancer Research and Clinical Oncology</i> , 2017, 143, 843-850.	1.2	34
84	A Pivotal Phase 2 Trial of Ponatinib in Patients with Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Resistant or Intolerant to Dasatinib or Nilotinib, or with the T315I BCR-ABL Mutation: 12-Month Follow-up of the PACE Trial. <i>Blood</i> , 2012, 120, 163-163.	0.6	34
85	INCB84344-201: Ponatinib and steroids in frontline therapy for unfit patients with Ph+ acute lymphoblastic leukemia. <i>Blood Advances</i> , 2022, 6, 1742-1753.	2.5	33
86	Advances in treatment of chronic myeloid leukemia with tyrosine kinase inhibitors: the evolving role of Bcr-Abl mutations and mutational analysis. <i>Pharmacogenomics</i> , 2012, 13, 1271-1284.	0.6	32
87	TREATMENT RECOMMENDATIONS FOR CHRONIC MYELOID LEUKEMIA. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2014, 6, e2014005.	0.5	32
88	Pleural effusion and molecular response in dasatinib-treated chronic myeloid leukemia patients in a real-life Italian multicenter series. <i>Annals of Hematology</i> , 2018, 97, 95-100.	0.8	32
89	Interferon-alfa for chronic myeloid leukemia. <i>Seminars in Hematology</i> , 2003, 40, 22-33.	1.8	32
90	Adult Acute Lymphoblastic Leukaemia: Study of 32 Patients and Analysis of Prognostic Factors. <i>Scandinavian Journal of Haematology</i> , 1979, 22, 154-164.	0.0	30



#	ARTICLE	IF	CITATIONS
91	Physicianâ€™s guide to the clinical management of adverse events on nilotinib therapy for the treatment of CML. <i>Cancer Treatment Reviews</i> , 2012, 38, 241-248.	3.4	29
92	Nilotinib in Chronic Myeloid Leukemia Patients in Chronic Phase (CMLCP) with Imatinib Resistance or Intolerance: 2-Year Follow-up Results of a Phase 2 Study.. <i>Blood</i> , 2008, 112, 3238-3238.	0.6	29
93	Update On Imatinib-Resistant Chronic Myeloid Leukemia Patients in Chronic Phase (CML-CP) On Nilotinib Therapy at 24 Months: Clinical Response, Safety, and Long-Term Outcomes.. <i>Blood</i> , 2009, 114, 1129-1129.	0.6	28
94	Moving towards patient-centered decision-making in chronic myeloid leukemia: assessment of quality of life and symptom burden. <i>Haematologica</i> , 2014, 99, 205-208.	1.7	27
95	A populationâ€based study of chronic myeloid leukemia patients treated with imatinib in first line. <i>American Journal of Hematology</i> , 2017, 92, 82-87.	2.0	27
96	Flai (fludarabine, cytarabine, idarubicin) plus lowâ€dose Gemtuzumab Ozogamicin as induction therapy in CD33â€positive AML: Final results and long term outcome of a phase II multicenter clinical trial. <i>American Journal of Hematology</i> , 2018, 93, 655-663.	2.0	27
97	Dasatinib Versus Imatinib In Patients with Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP) In the DASISION Trial: 18-Month Follow-up. <i>Blood</i> , 2010, 116, 206-206.	0.6	27
98	Long-term survivors in chronic granulocytic leukaemia: a study by the International CGL Prognosis Study Group. <i>British Journal of Haematology</i> , 1994, 87, 293-300.	1.2	25
99	Superior Complete Response Rate and Progression-Free Survival after Autologous Transplantation with up-Front Velcade-Thalidomide- Dexamethasone Compared with Thalidomide-Dexamethasone in Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2008, 112, 158-158.	0.6	25
100	In chronic myeloid leukemia patients on second-line tyrosine kinase inhibitor therapy, deep sequencing of BCR-ABL1 at the time of warning may allow sensitive detection of emerging drug-resistant mutants. <i>BMC Cancer</i> , 2016, 16, 572.	1.1	23
101	Nilotinib 300 mg twice daily: an academic single-arm study of newly diagnosed chronic phase chronic myeloid leukemia patients. <i>Haematologica</i> , 2016, 101, 1200-1207.	1.7	22
102	Healthâ€related quality of life in patients with chronic myeloid leukemia receiving firstâ€line therapy with nilotinib. <i>Cancer</i> , 2018, 124, 2228-2237.	2.0	22
103	Cryptic BCR-ABL fusion gene as variant rearrangement in chronic myeloid leukemia: molecular cytogenetic characterization and influence on TKIs therapy. <i>Oncotarget</i> , 2017, 8, 29906-29913.	0.8	22
104	Challenges for Allogeneic Hematopoietic Stem Cell Transplantation in Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors. <i>Acta Haematologica</i> , 2011, 126, 30-39.	0.7	21
105	Chronic Myeloid Leukemia Prognosis and Therapy: Criticisms and Perspectives. <i>Journal of Clinical Medicine</i> , 2020, 9, 1709.	1.0	21
106	Bisphosphonates and Osteonecrosis of the Jaws: Incidence in a Homogeneous Series of Patients with Newly Diagnosed Multiple Myeloma Treated with Zoledronic Acid.. <i>Blood</i> , 2005, 106, 3461-3461.	0.6	21
107	Line Treatment of Adult Ph+ Acute Lymphoblastic Leukemia (ALL) Patients. Final Results of the GIMEMA LAL1205 Study. <i>Blood</i> , 2008, 112, 305-305.	0.6	21
108	Pediatric Therapy In Adult Acute Lymphoblastic Leukemia: Updated Experience of a Single Centre. <i>Blood</i> , 2010, 116, 4338-4338.	0.6	21

#	ARTICLE	IF	CITATIONS
109	Second-generation BCR-ABL inhibitors for frontline treatment of chronic myeloid leukemia in chronic phase. <i>Critical Reviews in Oncology/Hematology</i> , 2012, 82, 159-170.	2.0	20
110	High and Early Rates of Cytogenetic and Molecular Response with Nilotinib 800 Mg Daily as First Line Treatment of Ph-Positive Chronic Myeloid Leukemia in Chronic Phase: Results of a Phase 2 Trial of the GIMEMA CML Working Party. <i>Blood</i> , 2008, 112, 181-181.	0.6	19
111	Dasatinib Time to and Durability of Major and Complete Cytogenetic Response (MCyR and CCyR) in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP). <i>Blood</i> , 2008, 112, 450-450.	0.6	19
112	Psychological well-being and social support in chronic myeloid leukemia patients receiving lifelong targeted therapies. <i>Supportive Care in Cancer</i> , 2016, 24, 4887-4894.	1.0	18
113	Validation of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 Summary Score in Patients With Hematologic Malignancies. <i>Value in Health</i> , 2019, 22, 1303-1310.	0.1	18
114	The IKK Inhibitor PS1145 Allows to Overcome Imatinib Resistance.. <i>Blood</i> , 2004, 104, 2940-2940.	0.6	18
115	Prognosis of patients with chronic myeloid leukemia presenting in advanced phase is defined mainly by blast count, but also by age, chromosomal aberrations and hemoglobin. <i>American Journal of Hematology</i> , 2019, 94, 1236-1243.	2.0	17
116	Mutations at Residues 315 and 317 in the ABL Kinase Domain Are the Main Cause of Resistance to Dasatinib in Philadelphia-Positive (Ph+) Leukemia Patients (pts).. <i>Blood</i> , 2006, 108, 836-836.	0.6	17
117	A Phase III Study of Enoxaparin Versus Low-Dose Warfarin Versus Aspirin as Thromboprophylaxis for Patients with Newly Diagnosed Multiple Myeloma Treated up-Front with Thalidomide-Containing Regimens. <i>Blood</i> , 2008, 112, 3017-3017.	0.6	17
118	24 Months Update of the TOPS Study: a Phase III, Randomized, Open-Label Study of 400mg/d (SD-IM) Versus 800mg/d (HD-IM) of Imatinib Mesylate (IM) in Patients (Pts) with Newly Diagnosed, Previously Untreated Chronic Myeloid Leukemia in Chronic Phase (CML-CP).. <i>Blood</i> , 2009, 114, 337-337.	0.6	17
119	Results From a Randomized Trial of Salvage Chemotherapy Followed by Lestaurtinib for FLT3 Mutant AML Patients in First Relapse.. <i>Blood</i> , 2009, 114, 788-788.	0.6	17
120	Successful treatment of multi-resistant <i>Pseudomonas aeruginosa</i> osteomyelitis after allogeneic bone marrow transplantation with a combination of colistin and tigecycline. <i>Journal of Medical Microbiology</i> , 2007, 56, 1692-1695.	0.7	16
121	Molecular Monitoring and Mutations in Chronic Myeloid Leukemia: How to Get the Most out of Your Tyrosine Kinase Inhibitor. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2014, , 167-175.	1.8	16
122	Dasatinib as Front-Line Monotherapy for the Induction Treatment of Adult and Elderly Ph+ Acute Lymphoblastic Leukemia (ALL) Patients: Interim Analysis of the GIMEMA Prospective Study LAL1205.. <i>Blood</i> , 2007, 110, 7-7.	0.6	16
123	The European LeukemiaNet: achievements and perspectives. <i>Haematologica</i> , 2011, 96, 156-162.	1.7	15
124	Incidence of second primary malignancies and related mortality in patients with imatinib-treated chronic myeloid leukemia. <i>Haematologica</i> , 2017, 102, 1530-1536.	1.7	15
125	PF-114: A 4th Generation Tyrosine Kinase-Inhibitor for Chronic Phase Chronic Myeloid Leukaemia Including BCRABL1T315I. <i>Blood</i> , 2019, 134, 1638-1638.	0.6	15
126	Efficacy of Dasatinib (SPRYCELÁ®) in Patients (pts) with Chronic Phase Chronic Myelogenous Leukemia (CP-CML) Resistant to or Intolerant of Imatinib: Updated Results of the CA180013 â€”START-Câ€™™ Phase II Study.. <i>Blood</i> , 2006, 108, 164-164.	0.6	15



#	ARTICLE	IF	CITATIONS
127	A Prospective Randomized Study Comparing Rituximab and Dexamethasone Vs Dexamethasone Alone in ITP: Results of Final Analysis and Long Term Follow up. <i>Blood</i> , 2008, 112, 1-1.	0.6	15
128	Long term outcome of Ph+ CML patients achieving complete cytogenetic remission with interferon based therapy moving from interferon to imatinib era. <i>American Journal of Hematology</i> , 2014, 89, 119-124.	2.0	14
129	Systematic review and meta-analysis of standard-dose imatinib vs. high-dose imatinib and second generation tyrosine kinase inhibitors for chronic myeloid leukemia. <i>Journal of Cancer Research and Clinical Oncology</i> , 2017, 143, 1311-1318.	1.2	14
130	Nilotinib in Patients (pts) with Relapsed/Refractory Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Who Are Resistant or Intolerant to Imatinib.. <i>Blood</i> , 2007, 110, 2815-2815.	0.6	14
131	Excellent Outcomes at 3 Years with Nilotinib 800 Mg Daily In Early Chronic Phase, Ph+ Chronic Myeloid Leukemia (CML): Results of a Phase 2 GIMEMA CML WP Clinical Trial. <i>Blood</i> , 2010, 116, 359-359.	0.6	14
132	First-line Therapy for Chronic Myeloid Leukemia: New Horizons and an Update. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2010, 10, 169-176.	0.2	13
133	Cytogenetic and Molecular Response to Imatinib in High Risk (Sokal) Chronic Myeloid Leukemia (CML): Results of An European Leukemianet Prospective Study Comparing 400 Mg and 800 Mg Front-Line. <i>Blood</i> , 2008, 112, 185-185.	0.6	13
134	Safety and Efficacy of Dasatinib (DAS) Vs. Imatinib (IM) by Baseline Comorbidity In Patients with Chronic Myeloid Leukemia In Chronic Phase (CML-CP): Analysis of the DASISION Trial.. <i>Blood</i> , 2010, 116, 3421-3421.	0.6	13
135	A CRITICAL HISTORY OF CHRONIC MYELOID LEUKEMIA. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2014, 6, e2014010.	0.5	12
136	Consistency matters: measurement invariance of the EORTC QLQ-C30 questionnaire in patients with hematologic malignancies. <i>Quality of Life Research</i> , 2020, 29, 815-823.	1.5	12
137	Superiority of Double over Single Autologous Stem Cell Transplantation as First-Line Therapy for Multiple Myeloma.. <i>Blood</i> , 2004, 104, 536-536.	0.6	12
138	BCR-ABL Mutations in Chronic Myeloid Leukemia (CML) Patients (pts) with Failure and Warning to First- and Second-Line Tyrosine Kinase Inhibitor (TKI) Therapy: What Is the Advantage of Next-Generation Sequencing (NGS) over Conventional Sequencing?. <i>Blood</i> , 2015, 126, 346-346.	0.6	12
139	Molecular Monitoring. <i>Current Hematologic Malignancy Reports</i> , 2014, 9, 1-8.	1.2	11
140	Molecular response in CML: where is the bar?. <i>Blood</i> , 2014, 124, 469-471.	0.6	11
141	Why chronic myeloid leukaemia cannot be cured by tyrosine kinase-inhibitors. <i>Leukemia</i> , 2021, 35, 2199-2204.	3.3	11
142	ENESTPath: A Phase 3 Study to Assess the Effect of Nilotinib Treatment Duration on Treatment-Free Remission (TFR) in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Previously Treated with Imatinib: 24-Month Analysis of the First 300 Patients in the Induction/Consolidation Phase. <i>Blood</i> , 2016, 128, 3094-3094.	0.6	11
143	The European Treatment and Outcome Study (EUTOS) for Chronic Myeloid Leukemia (CML). A Prospective, Population-Based European Registry.. <i>Blood</i> , 2009, 114, 4272-4272.	0.6	11
144	Effect of the tyrosine kinase inhibitor nilotinib in patients with hypereosinophilic syndrome/chronic eosinophilic leukemia: analysis of the phase 2, open-label, single-arm A2101 study. <i>Journal of Cancer Research and Clinical Oncology</i> , 2013, 139, 1985-1993.	1.2	10

#	ARTICLE	IF	CITATIONS
145	Definition and treatment of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia. Expert Review of Hematology, 2014, 7, 397-406.	1.0	10
146	Rotation of nilotinib and imatinib for first-line treatment of chronic phase chronic myeloid leukemia. American Journal of Hematology, 2016, 91, 617-622.	2.0	10
147	Validation and reference values of the EORTC QLQ-CML24 questionnaire to assess health-related quality of life in patients with chronic myeloid leukemia. Leukemia and Lymphoma, 2021, 62, 669-678.	0.6	10
148	Up-Front Thalidomide-Dexamethasone (THAL) and Double Autologous Transplantation (Double TX) for Multiple Myeloma: Comparison with Double TX without Added Thalidomide and Prognostic Implications of Chromosome 13 Deletion and Translocation t(4;14).. Blood, 2006, 108, 3081-3081.	0.6	10
149	Prognostic Value of BCR-ABL1 Transcript Type in Chronic Myeloid Leukemia Patients Treated Frontline with Nilotinib. Blood, 2016, 128, 3070-3070.	0.6	10
150	New Directions in the Treatment of Patients With Chronic Myeloid Leukemia: Introduction. Seminars in Hematology, 2009, 46, S1-S4.	1.8	9
151	Molecular response and quality of life in chronic myeloid leukemia patients treated with intermittent TKIs: First interim analysis of OPTIMA study. Cancer Medicine, 2021, 10, 1726-1737.	1.3	9
152	A Simple Clinical Prognostic Scoring System for Newly Diagnosed Cytogenetically Normal Acute Myeloid Leukemia: a Retrospective Analysis on 530 Patients. Blood, 2010, 116, 4848-4848.	0.6	9
153	Relationship of serum lactate dehydrogenase level with first remission length in adult acute lymphocytic leukaemia. British Journal of Haematology, 1987, 66, 49-53.	1.2	8
154	BCR-ABL1 compound mutants: prevalence, spectrum and correlation with tyrosine kinase inhibitor resistance in a consecutive series of Philadelphia chromosome-positive leukemia patients analyzed by NGS. Leukemia, 2021, 35, 2102-2107.	3.3	8
155	Nilotinib 800 Mg Daily as Frontline Therapy of Ph + Chronic Myeloid Leukemia: Dose Delivered and Safety Profile for the GIMEMA CML Working Party.. Blood, 2009, 114, 2205-2205.	0.6	8
156	Efficacy and Safety of Ponatinib in Patients with Accelerated Phase or Blast Phase Chronic Myeloid Leukemia (AP-CML or BP-CML) or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+) Tj ETQq000 rgBT #Overlock 1	0.6	8
157	Questions concerning tyrosine kinase-inhibitor therapy and transplants in chronic phase chronic myeloid leukaemia. Leukemia, 2022, 36, 1227-1236.	3.3	8
158	High-dose therapy followed by autologous bone marrow transplantation (ABMT) in previously untreated non-Hodgkin's lymphoma. European Journal of Haematology, 1986, 37, 347-352.	1.1	7
159	Bosutinib (SKI-606) Demonstrates Clinical Activity and Is Well Tolerated in Patients with AP and BP CML and Ph+ ALL.. Blood, 2008, 112, 1101-1101.	0.6	7
160	Efficacy and Safety of Ponatinib in CP-CML Patients By Number of Prior Tyrosine Kinase Inhibitors: 4-Year Follow-up of the Phase 2 PACE Trial. Blood, 2015, 126, 4025-4025.	0.6	7
161	Enestpath: A Phase III Study to Assess the Effect of Nilotinib Treatment Duration on Treatment-Free Remission (TFR) in Chronic Phase-Chronic Myeloid Leukemia (CP-CML) Patients (pts) Previously Treated with Imatinib: Interim Analysis from the First Year of Induction Phase. Blood, 2015, 126, 4040-4040.	0.6	7
162	Steady-State Imatinib Trough Levels as Well as Dose Interruptions Are Associated with Clinical Response (CCyR and MMR) and Adverse Events (AEs) in Patients with Chronic Myeloid Leukemia (CML) Receiving IM as Frontline Therapy.. Blood, 2009, 114, 2213-2213.	0.6	7

#	ARTICLE	IF	CITATIONS
163	In Ph+BCR-ABL1P210+ acute lymphoblastic leukemia the e13a2 (B2A2) transcript is prevalent. <i>Leukemia</i> , 2020, 34, 929-931.	3.3	6
164	Prognostic Factors for Overall Survival In Chronic Myeloid Leukemia Patients: A Multicentric Cohort Study by the Italian CML GIMEMA Network. <i>Frontiers in Oncology</i> , 2021, 11, 739171.	1.3	6
165	Fludarabine Based Regimen (FLA) Is an Effective Treatment for Induction of Multidrug Resistant Pgp-Positive Acute Myeloid Leukemia Patients.. <i>Blood</i> , 2005, 106, 1857-1857.	0.6	6
166	A Phase II Trial of CHOP Chemotherapy Followed by Yttrium 90 (90Y) Ibritumomab Tiuxetan (Zevalin®) for Previously Untreated Elderly Diffuse Large B-Cell Lymphoma (DLBCL) Patients.. <i>Blood</i> , 2006, 108, 2431-2431.	0.6	6
167	Superior Rate of Complete Response with up-Front Velcade-Thalidomide-Dexamethasone Versus Thalidomide-Dexamethasone in Newly Diagnosed Multiple Myeloma Is Not Affected by Adverse Prognostic Factors, Including High-Risk Cytogenetic Abnormalities.. <i>Blood</i> , 2008, 112, 1662-1662.	0.6	6
168	Imatinib (IM) Pharmacokinetic (PK) Exposure and Its Correlation with Clinical Outcome in Patients with Chronic-Phase Chronic Myeloid Leukemia (CML-CP) for 400 Mg and 800 Mg Daily Doses (Tyrosine) Tj ETQq0 00rgBT /Overlock 10		
169	Prognostic Factors for Progression-Free Survival in Patients with Imatinib-Resistant or -Intolerant Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Nilotinib Based On 24 Month Data.. <i>Blood</i> , 2009, 114, 3298-3298.	0.6	6
170	BCR-ABL Derived Peptide Vaccine in Chronic Myeloid Leukemia Patients with Molecular Minimal Residual Disease During Imatinib: Interim Analysis of a Phase 2 Multicenter GIMEMA CML Working Party Trial.. <i>Blood</i> , 2009, 114, 648-648.	0.6	6
171	Suppression of Bcr-Abl Expression in CML by A Panel of miRNAs.. <i>Blood</i> , 2009, 114, 854-854.	0.6	6
172	Bortezomib-Thalidomide-Dexamethasone Compared with Thalidomide-Dexamethasone as Induction and Consolidation Therapy Before and After Double Autologous Transplantation In Newly Diagnosed Multiple Myeloma: Results From a Randomized Phase 3 Study. <i>Blood</i> , 2010, 116, 42-42.	0.6	6
173	Interleukin-12 Gene Expression into Acute Myeloid Leukemia-Derived Dendritic Cells Overcomes T-Cell Functional Impairment Induced by Leukemic Microenvironment.. <i>Blood</i> , 2004, 104, 1816-1816.	0.6	6
174	Validation of the New European LeukemiaNet (ELN) Recommendations for Bcr-Abl Kinase Domain Mutation Analysis In Chronic Myeloid Leukemia: An Analysis of the GIMEMA CML Working Party Studies. <i>Blood</i> , 2011, 118, 112-112.	0.6	6
175	Current management of CML patients: Summary of the Italian Consensus Meeting held in Rome, April 11-12, 2013. <i>Critical Reviews in Oncology/Hematology</i> , 2014, 90, 181-189.	2.0	5
176	A Novel 4-anilino-3-quinolinecarbonitrile Dual Src and Abl Kinase Inhibitor (SKI-606) Has In Vitro Activity on CML Ph+Blast Cells Resistant to Imatinib.. <i>Blood</i> , 2004, 104, 1991-1991.	0.6	5
177	Whole-Transcriptome Sequencing In Chronic Myeloid Leukemia Reveals Novel Gene Mutations That May Be Associated with Disease Pathogenesis and Progression. <i>Blood</i> , 2010, 116, 885-885.	0.6	5
178	The BCR-ABL1 Transcript Type Does Not Influence the Response and the Outcome of Chronic Myeloid Leukemia Patients Treated Frontline with Nilotinib. <i>Blood</i> , 2012, 120, 1680-1680.	0.6	5
179	Molecular Responses with Ponatinib in Patients with Philadelphia Chromosome Positive (Ph+) Leukemia: Results From the PACE Trial. <i>Blood</i> , 2012, 120, 3763-3763.	0.6	5
180	Long Term Follow-up of Ph+ CML Patients Achieving Complete Cytogenetic Response (CCgR) with Interferon Based Therapy - GIMEMA Protocol CML0509. <i>Blood</i> , 2011, 118, 786-786.	0.6	5

#	ARTICLE	IF	CITATIONS
181	Collection of Hematopoietic Stem Cells After Previous Exposure to Itrium-90 Ibritumumab Tiuxetan (Zevalin) Is Feasible and Does Not Impair Autologous Stem Cell Transplantation Outcome in Follicular Lymphoma.. Blood, 2012, 120, 3019-3019.	0.6	5
182	Resistance to Tyrosine Kinase Inhibitors in Philadelphia Chromosome-Positive Leukemias: Which Mutations Matter?. Clinical Leukemia, 2007, 1, 223-228.	0.2	4
183	New drugs and allogeneic hematopoietic stem cell transplantation for hematological malignancies: do they have a role in bridging, consolidating or conditioning transplantation treatment?. Expert Opinion on Biological Therapy, 2017, 17, 821-836.	1.4	4
184	MEC (mitoxantrone, etoposide, and cytarabine) induces complete remission and is an effective bridge to transplant in acute myeloid leukemia. European Journal of Haematology, 2020, 105, 47-55.	1.1	4
185	A New Abl Kinase Inhibitor (AMN107) Has In Vitro Activity on CML Ph+Blast Cells Resistant to Imatinib.. Blood, 2004, 104, 4687-4687.	0.6	4
186	Frequency, Distribution and Prognostic Value of ABL Kinase Domain (KD) Mutations in Different Subsets of Philadelphia-Positive (Ph+) Patients (Pts) Resistant to Imatinib (IM) by the Gimema Working Party on CML.. Blood, 2005, 106, 435-435.	0.6	4
187	Phase II Study of Proteasome Inhibitor Bortezomib (Velcade®) in Patients with Relapsed/Refractory T-Cell Lymphoma: Preliminary Results.. Blood, 2006, 108, 2462-2462.	0.6	4
188	A Prospective Study of Imatinib 400 mg vs 800 mg Frontline in High Risk Ph+ Chronic Myeloid Leukemia (CML) Patients.. Blood, 2007, 110, 26-26.	0.6	4
189	Gene Expression Profile (GEP) of Chronic Myeloid Leukemia (CML) Patients at Diagnosis: Two Distinguished Subgroups of CML Patients Identified, Based on a Molecular Signature, Irrespective of Their Sokal Risk Score. Blood, 2008, 112, 3190-3190.	0.6	4
190	Philadelphia-Positive Acute Lymphoblastic Leukemia Patients Already Harbor Bcr-Abl Kinase Domain Mutations at Low Levels at the Time of Diagnosis - a Report by the GIMEMA ALL Working Party. Blood, 2008, 112, 722-722.	0.6	4
191	International Development of An EORTC Measure to Assess Patient-Reported Quality of Life (QoL) and Symptoms in Chronic Myeloid Leukemia (CML). Blood, 2011, 118, 3132-3132.	0.6	4
192	Superiority of First-Line Thalidomide-Dexamethasone over Vincristine-Doxorubicin-Dexamethasone in Preparation for Autologous Stem Cell Transplantation for Multiple Myeloma.. Blood, 2004, 104, 1489-1489.	0.6	4
193	Imatinib 800 mg: Preliminary Results of a Phase II Trial of the GIMEMA CML Working Party in Intermediate Sokal Risk Patients and Status-of-the-Art of an Ongoing Multinational, Prospective Randomized Trial of Imatinib Standard Dose (400 mg Daily) vs High Dose (800 mg Daily) in High Sokal Risk Patients.. Blood, 2005, 106, 1098-1098.	0.6	4
194	A Review and an Update of European LeukemiaNet Recommendations for the Management of Chronic Myeloid Leukemia. Hematologic Malignancies, 2016, , 55-69.	0.2	3
195	Chronic myeloid leukemia: room for improvement?. Haematologica, 2017, 102, 1131-1133.	1.7	3
196	Ten-Year Follow-up of Patients with Chronic Myeloid Leukemia Treated with Nilotinib in First-Line: Final Results of the Gimema CML 0307 Trial. Blood, 2019, 134, 4145-4145.	0.6	3
197	Imatinib Mesylate Can Induce Molecular Complete Remission in Idiopathic Hypereosinophilic Syndrome (HES). A Phase II Multicentric Italian Clinical Trial.. Blood, 2005, 106, 375-375.	0.6	3
198	The Combination of Interferon-Alpha with Imatinib in Early Chronic Phase Chronic Myeloid Leukemia Patients Induces a Significant Improvement of the Molecular Responses in the First Two Years of Treatment: Results From Three Studies From the GIMEMA CML Working Party.. Blood, 2009, 114, 2192-2192.	0.6	3

#	ARTICLE	IF	CITATIONS
199	Phase II Multicentric Explorative Study of Intermittent Imatinib (IM) Treatment (INTERIM) in Elderly Patients with Ph+ Chronic Myeloid Leukemia (CML) Who Achieved a Stable Complete Cytogenetic Response (CCgR) with Standard IM Therapy.. Blood, 2009, 114, 860-860.	0.6	3
200	PF-04449913 Reverts Multi Drug Resistance (MDR) by a Strong Down-Regulation of ABCA2 and BCL2 on Leukemia Stem Cells in Phase I Acute Myeloid Leukemia and Chronic Myeloid Leukemia Treated Patients. Blood, 2011, 118, 1429-1429.	0.6	3
201	Gas1 and Kif27 Genes Are Strongly up-Regulated Biomarkers of Hedgehog Inhibition (PF-04449913) on Leukemia Stem Cells in Phase I Acute Myeloid Leukemia and Chronic Myeloid Leukemia Treated Patients. Blood, 2011, 118, 1535-1535.	0.6	3
202	Identification of Genes Sustaining Bcr-Abl Oncogenic Signalling and CML Progression through a Genetic Tool Based on Human Bcr-Abl Transgenic Drosophila Melanogaster.. Blood, 2008, 112, 1091-1091.	0.6	3
203	Current treatment approaches in CML. HemaSphere, 2019, 3, 54-56.	1.2	2
204	A New Abl Kinase Inhibitor (AMN107) Has In Vitro Activity on Chronic Myeloid Leukaemia (CML) Ph+ Cells Resistant to Imatinib.. Blood, 2005, 106, 2004-2004.	0.6	2
205	Comparison of Steady-State Imatinib (IM) Trough Levels, Clinical Response, and Safety Between Caucasian and Asian Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with 400mg and 800mg Daily Doses of IM in the Tyrosine Kinase Inhibitor Optimization and Selectivity (TOPS) Study.. Blood, 2009, 114, 1127-1127.	0.6	2
206	Hydroxyurea Treatment In 1075 Patients with Essential Thrombocythemia and Occurrence of Extra-Hematological Adverse Events: A Preliminary Report of the Registro Italiano Trombocitemia (RIT). Blood, 2010, 116, 1973-1973.	0.6	2
207	Occurrence, Management, and Outcomes In Patients with Pleural Effusion During Dasatinib Treatment for Chronic-Phase Chronic Myeloid Leukemia (CML-CP) In the First-Line Setting: Analysis of the DASISION Trial. Blood, 2010, 116, 2282-2282.	0.6	2
208	Subcutaneous Omacetaxine (OM) Treatment of Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Patients Following Multiple Tyrosine Kinase Inhibitor (TKI) Failure. Blood, 2010, 116, 2290-2290.	0.6	2
209	EUTOS Score Is Also Valid in CML Patients Not Involved in Clinical Studies. Blood, 2012, 120, 3759-3759.	0.6	2
210	Frontline Treatment With Imatinib Mesylate in Chronic Myeloid Leukemia Patients in Early Chronic Phase: a Very Long-Term Analysis by the GIMEMA CML Working Party. Blood, 2013, 122, 258-258.	0.6	2
211	Long-Term Outcome to First-Line Imatinib according to 2013 European LeukemiaNet Response Criteria: a GIMEMA CML WP Analysis. Blood, 2015, 126, 2792-2792.	0.6	2
212	Phase I/II Study of Tipifarnib and Bortezomib in the Treatment of Poor Risk Adult Acute Myeloid Leukemia. Blood, 2008, 112, 2982-2982.	0.6	2
213	PAX5 Wild-Type without IKZF1 (Ikaros) Deletion Is Associated with Prolonged Disease-Free Survival and Low Rate of Cumulative Incidence of Relapse in Adult BCR-ABL1-Positive Acute Lymphoblastic Leukemia (ALL): On Behalf of GIMEMA AL Working Party.. Blood, 2009, 114, 12-12.	0.6	2
214	BCR-ABL Fusion Transcript Do Not Significantly Influence the Outcome of Chronic Myeloid Leukemia Patients In Early Chronic Phase Treated with Imatinib Mesylate: a GIMEMA CML WP Analysis.. Blood, 2010, 116, 1230-1230.	0.6	2
215	Effect of Lenalidomide Treatment on Lipid Signalling Pathways in Low-Risk MDS Patients. Blood, 2011, 118, 4635-4635.	0.6	2
216	Clinical Relevance of Low Burden BCR-ABL1 Mutations Detectable By Amplicon Deep Sequencing (DS) in Philadelphia-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Patients (pts): The Type of Mutation Matters. Blood, 2015, 126, 2489-2489.	0.6	2



#	ARTICLE	IF	CITATIONS
217	Treatment of chronic myeloid leukemia, which drugs? How long? How much?. International Journal of Hematologic Oncology, 2015, 4, 93-97.	0.7	1
218	Managing children with chronic myeloid leukaemia. British Journal of Haematology, 2015, 169, 759-760.	1.2	1
219	A Review and an Update of European LeukemiaNet Recommendations for the Management of Chronic Myeloid Leukemia. Hematologic Malignancies, 2021, , 145-158.	0.2	1
220	Quality of Life Improvements in Patients with Chronic Myeloid Leukemia after Stopping Long-Term Therapy: Who Can Benefit the Most?. Journal of the National Cancer Institute, 2021, , .	3.0	1
221	European Multicenter Experience on Idiopathic Hypereosinophilic Syndrome (HES) with FIP1L1-PDGFR $\alpha$ Rearrangement treated with Imatinib.. Blood, 2004, 104, 1507-1507.	0.6	1
222	Better Molecular Response (MR) to Imatinib (IM) in Early Chronic Phase (CP) Versus Late CP Chronic Myeloid Leukemia (CML) Patients (pts) in Complete Cytogenetic Response (CCR): A Comparison at 24 Months of 2 Clinical Trials of the GIMEMA Working Party on CML on Behalf of the GIMEMA Working Party on Chronic Myeloid Leukemia (GIMEMA-CML).. Blood, 2005, 106, 1096-1096.	0.6	1
223	Bortezomib-Thalidomide-Dexamethasone as Primary Induction Therapy for Newly Diagnosed Multiple Myeloma Significantly Decreases Bone Resorption While Sparing Bone Formation as Compared to Thalidomide-Dexamethasone. Blood, 2008, 112, 5117-5117.	0.6	1
224	High-Resolution Molecular Allelokaryotyping of Chronic Myeloid Leukemia Patients in Blast Crisis by 6.0 SNP-Arrays Shows a High-Frequency of Uniparental Disomy and Focal Copy Number Alterations Affecting the Whole Sequence or Specific Exons of Oncogenes and Tumor Suppressor Genes.. Blood, 2009, 114, 2176-2176.	0.6	1
225	Chronic Eosinophilic Leukaemia (CEL) with FIP1L1-PDGFR $\alpha$ Rearrangement (F/P): The Response to Imatinib (IM) Is Durable. A Report of 33 Patients with A Follow up of 30 to 92 Months.. Blood, 2009, 114, 3894-3894.	0.6	1
226	Epigenetic Regulation of Lipid Signalling Pathways In Low-Risk MDS Patients During Azacitidine Treatment. Blood, 2010, 116, 233-233.	0.6	1
227	Alternating Nilotinib 400 mg twice daily and Imatinib 400 mg once daily as Frontline Treatment of Ph+ Chronic Myeloid Leukemia. A Phase 2 Multicentric Study of the GIMEMA CML Working Party. Blood, 2011, 118, 453-453.	0.6	1
228	Treatment and Outcome Analysis of 2,904 Patients from the EUTOS Population Based Registry. Blood, 2015, 126, 2780-2780.	0.6	1
229	Impact of Age on Efficacy and Toxicity of Nilotinib in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP): ENEST1st Sub-Analysis. Blood, 2015, 126, 479-479.	0.6	1
230	Impact of Age on Efficacy, Safety, and Long-Term Outcome of Chronic Myeloid Leukemia (CML) Patients Treated in First-Line with Nilotinib: An Analysis of the Gimema CML Working Party. Blood, 2016, 128, 3068-3068.	0.6	1
231	Gene Expression Profile in the CML Cell Line K562 Treated with SKI-606, a Dual Inhibitor of Src/Abl Kinase.. Blood, 2005, 106, 4870-4870.	0.6	1
232	Good Prognosis of CML Patients with Clonal Cytogenetic Abnormalities in Ph-Negative Cells.. Blood, 2005, 106, 1082-1082.	0.6	1
233	Report of a Phase II Study of Proteasome Inhibitor Bortezomib (Velcade) in Patients with Relapsed or Refractory T-Cell Lymphoma.. Blood, 2005, 106, 4764-4764.	0.6	1
234	Gene Expression Analysis of Peripheral T-Cell Lymphoma Not Otherwise Specified Reveals the Existence of Two Subgroups Related to Different Cellular Counterparts and Recurrent PDGFR $\alpha$ Deregulation.. Blood, 2005, 106, 1217-1217.	0.6	1



#	ARTICLE	IF	CITATIONS
235	RASGRP1/APTX Ratio Strongly Correlates with Clinical Response and Survival in AML Patients Treated with Tipifarnib-Bortezomib Combination.. Blood, 2009, 114, 1028-1028.	0.6	1
236	Identification of Rab5 as a Gene Involved in Chronic Myeloid Leukemia (CML) Progression.. Blood, 2009, 114, 3470-3470.	0.6	1
237	Efficacy and Feasibility of Nelarabine Savage Therapy In Adult Relapsed or Refractory T Cell Acute Lymphoblastic Leukemia (T-ALL) and Lymphoblastic Lymphoma (T-LBL) Strongly Indicates the Introduction of a Nelarabine-Based First Line Regimen. Blood, 2010, 116, 4335-4335.	0.6	1
238	Nilotinib Exposure-Response Analysis In Patients with Imatinib-Resistant or -Intolerant Chronic Myeloid Leukemia (CML). Blood, 2010, 116, 890-890.	0.6	1
239	CD133+ Pluripotent Stem Cells for the Treatment of Chronic Liver Failure.. Blood, 2010, 116, 1185-1185.	0.6	1
240	The Small Molecule CHK1/CHK2 Inhibitor PF-0477736 (Pfizer) Demonstrates Single Agent Activity and Synergizes with Chemotherapy in Diffuse Large B-Cell Lymphoma. Blood, 2011, 118, 2732-2732.	0.6	1
241	Subcutaneous Omacetaxine in Chronic or Accelerated Chronic Myeloid Leukemia Resistant to Two or More Tyrosine-Kinase Inhibitors Including Imatinib,. Blood, 2011, 118, 3761-3761.	0.6	1
242	Reply to A. JimÃ©nez-Velasco et al. Journal of Clinical Oncology, 2010, 28, e311-e311.	0.8	0
243	Interview: Forty years of dedication to chronic myeloid leukemia. International Journal of Hematologic Oncology, 2012, 1, 119-120.	0.7	0
244	The challenge to chronic myeloid leukemia: are we close to cure?. International Journal of Hematologic Oncology, 2012, 1, 3-6.	0.7	0
245	Nilotinib against high dose imatinib for salvage therapy of chronic myeloid leukaemia. Lancet Haematology,the, 2016, 3, e554-e555.	2.2	0
246	Safety Profiles of First-Line TKIs and Managing Adverse Effects. , 2016, , 161-166.		0
247	Physiciansâ€™ attitude towards selection of second line therapy with nilotinib and dasatinib in chronic myeloid leukemia patients. Health and Quality of Life Outcomes, 2017, 15, 204.	1.0	0
248	Perspectives and Emotional Experiences of Patients With Chronic Myeloid Leukemia During ENESTPath Clinical Trial and Treatment-Free Remission: Rationale and Protocol of the Italian Substudy. Frontiers in Oncology, 2021, 11, 638689.	1.3	0
249	Imatinib Therapy for Chronic Myeloid Leukemia Patients Who Relapse after Allogeneic Stem Cell Transplantation: A Molecular Analysis.. Blood, 2004, 104, 4655-4655.	0.6	0
250	Thalidomide-Induced Peropheral Neuropathy in Newly Diagnosed and Pre-Treated Multiple Myeloma Patients.. Blood, 2004, 104, 4898-4898.	0.6	0
251	Imatinib in the Treatment of CML Patients â‰¥ 65 Years Old in Late Chronic Phase: Results of a Phase II Study of the GIMEMA CML Working Party.. Blood, 2004, 104, 2935-2935.	0.6	0
252	Purification of Allogeneic Idiotype-Specific T Lymphocytes According to IFN-Î³ Production for Adoptive Immunotherapy in Multiple Myeloma Patients.. Blood, 2004, 104, 2119-2119.	0.6	0

#	ARTICLE	IF	CITATIONS
253	Prediction of Response to Imatinib by Prospective Quantitation of BCR-ABL Transcript in Late Chronic Phase Chronic Myeloid Leukemia PatientsBy GIMEMA Working Party on CML.. Blood, 2004, 104, 4672-4672.	0.6	0
254	Efficacy and Toxicity of FLAI-G-CSF and Mylotarg for Induction/Consolidation of AML Patients, Not Treatable with Conventional Chemotherapy.. Blood, 2004, 104, 4514-4514.	0.6	0
255	Superior Complete Remission/Very Good Partial Remission Rate with Peri-Transplant Administration of Thalidomide-Dexamethasone for Newly Diagnosed Multiple Myeloma.. Blood, 2005, 106, 5474-5474.	0.6	0
256	Imatinib Mesylate Determines a High Frequency of Major Molecular Responses in Newly Diagnosed Philadelphia Chromosome-Positive Chronic Phase Chronic Myeloid Leukemia (CML) on Behalf of the GIMEMA Working Party on Chronic Myeloid Leukemia (GIMEMA-CML).. Blood, 2005, 106, 1100-1100.	0.6	0
257	Antiproliferative Effects of Tyrosine Kinase (STI 571) and Farnesyl Transferase Inhibitors (R115777 and) Tj ETQq1 1 0,784314,0gBT /Over	0.6	0
258	Marker Expression in Peripheral T-Cell Lymphoma Unspecified: Proposal of a Clinical-Pathologic Prognostic Score.. Blood, 2005, 106, 2819-2819.	0.6	0
259	A Phase II Trial of CHOP Chemotherapy Followed by Yttrium 90 (90Y) Ibritumomab Tiuxetan (Zevalin) for Previously Untreated Elderly Diffuse Large B-Cell Lymphoma (DLBCL) Patients.. Blood, 2005, 106, 4765-4765.	0.6	0
260	SU11657, a FLT3-Targeted Tyrosine Kinase, Has Pro-Apoptotic Activity on Leukemia Cells In Vitro.. Blood, 2005, 106, 2797-2797.	0.6	0
261	A Phase II Trial of FM (Oral Fludarabine and Mitoxantrone) Chemotherapy Followed by Yttrium 90 (90Y) Ibritumomab Tiuxetan (Zevalin) for Previously Untreated Follicular Lymphoma (FL) Patients.. Blood, 2005, 106, 4763-4763.	0.6	0
262	In Vitro and In Vivo Induction of Human Hematopoietic Stem Cell Migration by Extracellular UTP.. Blood, 2005, 106, 1730-1730.	0.6	0
263	Comparison of Cytogenetics and Interphase Fluorescence In Situ Hybridization in Newly Diagnosed Ph+ Chronic Myeloid Leukemia Patients Treated with Imatinib Mesylate. A Study by the GIMEMA Working Party on CML. On Behalf of GWP on CML.. Blood, 2005, 106, 4857-4857.	0.6	0
264	Bone Involvement in Multiple Myeloma Patients Carrying the T (4;14) Chromosomal Translocation.. Blood, 2006, 108, 4996-4996.	0.6	0
265	Acute Myeloid Leukemia-Derived Dendritic Cells Express the Immunoregulatory Enzyme Indoleamine 2,3-dioxygenase.. Blood, 2006, 108, 1899-1899.	0.6	0
266	Direct and Coordinate Regulation of Multidrug Resistance Genes by the c-Myc Oncoprotein.. Blood, 2006, 108, 2594-2594.	0.6	0
267	FLT-3 Activity and Its Response to Drugs Can Be Determined in AML Blast Cells by FLT-3 Phosphorylation Status Using Flow Cytometry.. Blood, 2006, 108, 2308-2308.	0.6	0
268	NPM Mutations and Not FLT3 Mutations Are a Potential Marker for Monitoring Minimal Residual Disease in Acute Myeloid Leukemia.. Blood, 2006, 108, 2016-2016.	0.6	0
269	The European Leukemia Net CML Registry - Objectives, Achievements and First Results.. Blood, 2006, 108, 4781-4781.	0.6	0
270	Impact of Age in the Outcome of Patients with Chronic Myeloid Leukemia in Late Chronic Phase: Clinical and Molecular Results of a Phase II Study of the GIMEMA CML Working Party.. Blood, 2006, 108, 4805-4805.	0.6	0

#	ARTICLE	IF	CITATIONS
271	Prevalence and Prognostic Significance of FLT3 Mutations in Acute Myeloid Leukemia: Association of ITDs with Poor Outcome in Patients with Normal Cytogenetics.. Blood, 2006, 108, 2017-2017.	0.6	0
272	A Phase II Trial of FM (Fludarabine and Mitoxantrone) Chemotherapy Followed by Yttrium 90 (90Y) Ibritumomab Tiuxetan (Zevalin®) for Previously Untreated Indolent Non-Follicular Lymphoma Patients.. Blood, 2006, 108, 2478-2478.	0.6	0
273	Superiority of Double over Single Autologous Stem-Cell Transplantation for Newly Diagnosed Multiple Myeloma and Prognostic Impact of Complete Response: Final Analysis of the Bologna 96 Study.. Blood, 2007, 110, 730-730.	0.6	0
274	Identification and Molecular Characterization of Two Recurrent Genomic Deletions (Type A and Type) Tj ETQq0 0 0 rgBT /Overlock 10 Tf Behalf of the GIMEMA ALL Working Party. Blood, 2008, 112, 428-428.	0.6	0
275	Induction Intensified Regimens Including Fludarabine or Mylotarg for Acute Myeloid Leukemia Patients: Comparison by Response and Follow-up.. Blood, 2008, 112, 941-941.	0.6	0
276	Different Isoforms of the B-Cell Mutator Activation-Induced Cytidine Deaminase (AID) Are Aberrantly Over-Expressed in BCR-ABL1-Positive Acute Lymphoblastic Leukemia (ALL) Patients and Promote Genetic Instability.. Blood, 2008, 112, 1497-1497.	0.6	0
277	Dietary Supplement Vitamin C Significantly Abrogates Bortezomib-Induced Multiple Myeloma (MM) Cell Growth Inhibition. Blood, 2008, 112, 3687-3687.	0.6	0
278	A New Risk Score for Invasive Aspergillosis in Patients with Haematological Malignancies.. Blood, 2008, 112, 1469-1469.	0.6	0
279	Efficacy and Clinical Outcome of Philadelphia (Ph) Positive Acute Lymphoblastic Leukemia (ALL) Patients Treated with Second Generation Tyrosine Kinase Inhibitors (TKIs): The Bologna Experience.. Blood, 2009, 114, 2027-2027.	0.6	0
280	Clinical and Prognostic Relevance of Magnetic Resonance Imaging of the Spine in Newly Diagnosed Multiple Myeloma Patients Receiving Autologous Stem Cell Transplantation.. Blood, 2009, 114, 4885-4885.	0.6	0
281	Disabled Gene Is Involved in CML Progression and Its Expression Level at Diagnosis Can Predict Major Molecular Response (MMR) to Imatinib Therapy.. Blood, 2009, 114, 3964-3964.	0.6	0
282	Four Drugs Combination (Fludarabine, Cytarabine, Idarubicin, Etoposide) as Induction Therapy for Newly Diagnosed Acute Myeloid Leukemia Patients Younger Than 65 Ys: Response and Follow-up of 84 Patients.. Blood, 2009, 114, 4147-4147.	0.6	0
283	Thalidomide-Dexamethasone as Induction Therapy Prior to Autologous Stem-Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma and Renal Failure.. Blood, 2009, 114, 4934-4934.	0.6	0
284	Outcome and Prognosis of 1955 Patients with Chronic Myeloid Leukemia: First Results of the CML-Registry of the European Treatment and Outcome Study EUTOS.. Blood, 2009, 114, 1109-1109.	0.6	0
285	Effect of Erythropoietin Treatment on Lipid Signalling Pathways in Low-Risk MDS Patients.. Blood, 2009, 114, 2384-2384.	0.6	0
286	CD34+ obtained from High Sokal Risk Chronic Myeloid Leukemia (CML) Patients (PTS) Expresses Gene Profiles (GEP) Significantly Different From CD34+ Obtained From Low Sokal Risk Patients.. Blood, 2009, 114, 2174-2174.	0.6	0
287	Association Between Imatinib (IM) Transporters and Metabolizing Enzymes Genotype and Response in Newly Diagnosed Chronic Myeloid Leukemia (CML) Patients (Pts) Is Influenced by Ethnicity.. Blood, 2009, 114, 3283-3283.	0.6	0
288	The Inactivation of the Tumor Suppressor Genes CDKN2A/ARF by Genomic Deletions Frequently Occurs and Worsens Prognosis In Adult BCR-ABL1 Positive Acute Lymphoblastic Leukemia (ALL) Patients. Blood, 2010, 116, 3136-3136.	0.6	0

#	ARTICLE	IF	CITATIONS
289	Health-Related Quality of Life In Patients with Chronic Myeloid Leukemia: What Have We Learned Over the Last Twenty Years?.. Blood, 2010, 116, 3423-3423.	0.6	0
290	Low-Level Bcr-Abl Kinase Domain Mutations Are Very Rare In Chronic Myeloid Leukemia Patients Who Are In Major Molecular Response After 12 Months of First-Line Nilotinib Therapy.. Blood, 2010, 116, 1666-1666.	0.6	0
291	RASGRP1/APTX Ratio Is a Strong Biomarker of Clinical Response and Survival In AML Patients Treated with Tipifarnib: A Phase III Preliminary Results. Blood, 2010, 116, 4359-4359.	0.6	0
292	Long Term Study of the Impact of Quantitative Molecular Monitoring of Bcr-Abl Transcripts on the Risk of Relapse of CML After Allogeneic HSCT.. Blood, 2010, 116, 1287-1287.	0.6	0
293	Incidence and Mortality of Second Malignancies In 559 Patients with Chronic Myeloid Leukemia (CML) Treated with Imatinib Frontline: Data From the GIMEMA CML Working Party. Blood, 2010, 116, 2281-2281.	0.6	0
294	The Immunoregulatory Enzyme Indoleamine 2,3-Dioxygenase (IDO1) Is Expressed by Natural Killer (NK) Cells During Cytokine-Mediated Activation. Blood, 2010, 116, 3894-3894.	0.6	0
295	Evaluating the Response to Imatinib In Philadelphia-Positive Chronic Myeloid Leukemia (Ph+ CML): The Value of Major Molecular Response (MMoR) at 12 Months. Blood, 2010, 116, 668-668.	0.6	0
296	Health-Related Quality of Life In Patients with Chronic Myeloid Leukemia Undergoing First Line Treatment with Imatinib for at Least Three Years Compared with the General Population. A Multicenter Study Including 448 Patients. Blood, 2010, 116, 2273-2273.	0.6	0
297	Identification of A Pharmacogenomic Profile Associated with High Sensitivity and Low Toxicity to a Combination of Gemtuzumab Ozogamicin Plus Fludarabine, Cytarabine, Idarubicin Regimen In CD33-Positive Acute Myeloid Leukemia (AML) Patients. Blood, 2010, 116, 967-967.	0.6	0
298	Extreme Variability of FIP1L1-PDGFRalpha Transcripts In CEL: Analysis of 32 Patients Enrolled In HES0203 Italian Clinical Trial and Correlation with Clinical and Molecular Response After 5 Years Follow-up. Blood, 2010, 116, 1986-1986.	0.6	0
299	Drug Resistance and Bcr-Abl Kinase Domain Mutations In Philadelphia-Positive Acute Lymphoblastic Leukemia From the Imatinib to the 2nd-Generation Tyrosine Kinase Inhibitor Era: The Main Changes Are In the Type of Mutations, but Not In the Frequency of Mutation Involvement. Blood, 2011, 118, 575-575.	0.6	0
300	Fludarabine and Mitoxantrone Followed by Yttrium-90 Ibritumumab Tiuxetan in Untreated Patients with Follicular Lymphoma. Long Term Efficacy and Toxicity Results of the FLUMIZ Trial.. Blood, 2011, 118, 1604-1604.	0.6	0
301	Investigating Personal and Treatment Related Factors Associated with Adherence Behavior in Patients with Chronic Myeloid Leukemia Receiving Long Term Imatinib Therapy. Blood, 2011, 118, 1026-1026.	0.6	0
302	PKC412 (Midostaurin) Is Safe and Highly Effective in Systemic Mastocytosis Patients: The Bologna Experience. Blood, 2012, 120, 1749-1749.	0.6	0
303	Algorithms and Processing Pipeline For Error Correction and Detection Of Significant Mutations In The Kinase Domain Of BCR-ABL Analyzed By Next-Generation Sequencing: Implications For Clinical Practice Of Chronic Myeloid Leukemia. Blood, 2013, 122, 3987-3987.	0.6	0
304	The e13a2 BCR-ABL1 Fusion Transcript Is a Candidate Adverse Prognostic Factor In Chronic Myeloid Leukemia Patients Treated Frontline With Imatinib Mesylate. Blood, 2013, 122, 1486-1486.	0.6	0
305	Evaluation of the Benefit/Risk Profile of Ponatinib in CP-CML Patients over Time: 4-Year Follow-up of the Phase 2 PACE Study. Blood, 2015, 126, 5142-5142.	0.6	0
306	Prospective Metabolic and Cardiovascular Assessment in Chronic Phase Chronic Myeloid Leukemia Patients Treated with Nilotinib 300 Mg Bid Frontline in the Gimema 0811 Trial. Blood, 2015, 126, 4046-4046.	0.6	0

#	ARTICLE	IF	CITATIONS
307	Assessment of BCR-ABL1 Transcript Levels By Digital PCR (dPCR) in CML Patients who Achieved a Deep Molecular Response (DMR: MR4.0, MR4.5 And MR5.0) with Tkis May Improve the Detection of Minimal Residual Disease (MRD) and the Selection of Patients for Treatment Free Remission (TFR). Blood, 2016, 128, 3096-3096.	0.6	0
308	A Population-Based Study of Chronic Myeloid Leukemia Treated with Imatinib in First Line. Blood, 2016, 128, 3076-3076.	0.6	0
309	Predictive Factors for Overall Survival in Chronic Myeloid Leukemia Patients: An Analysis By the Gimema Cml Italian Study. Blood, 2020, 136, 47-48.	0.6	0